Dyne wins new Outperform at BMO
Dyne Therapeutics (NASDAQ:DYN) Coverage Initiated by Analysts at BMO Capital Markets
Stock analysts at BMO Capital Markets started coverage on shares of Dyne Therapeutics (NASDAQ:DYN – Get Free Report) in a report released on Wednesday, Marketbeat Ratings reports. The brokerage set an “outperform” rating and a $50.
BMO Capital Markets initiated coverage on Dyne Therapeutics, Inc. (NASDAQ:DYN), focused on developing therapies for ...
Dyne Therapeutics’ DYNE-101 shows positive results in phase 1/2 ACHIEVE study. Read why DYN stock may rise with FDA approval and a $2.78B market opportunity.
A live webcast will be available in the Investors & Media section of Dyne’s website at https://investors.dyne-tx.com/news-and-events/events-and-presentations and a replay will be accessible for 90 ...
Dyne Therapeutics, Inc. (NASDAQ:DYN – Get Free Report)’s share price was down 6.4% during mid-day trading on Monday after Piper Sandler lowered their price target on the stock from $53.00 to $48.00.
Full enrollment of Registrational Expansion Cohort of ACHIEVE Trial of DYNE-101 in DM1 Planned for Mid-2025 to Support Submission for U.S. Accelerated Approval - - Full Enrollment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback